Nanocrystal technology in the delivery of poorly soluble drugs: An overview

Current Drug Delivery

Volumn 8, Issue 4, 2011, Pages 398-406

  Nagarwal, Ramesh C ^a   Kumar, Rakesh ^a   Dhanawat, Meenakshi ^a   Das, Nirupam ^a   Pandit, J K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Drug delivery; Drugs; Nanocrystal; Nanocrystallization

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; ATOVAQUONE; AZITHROMYCIN; BECLOMETASONE; CLOZAPINE; CORTICOSTEROID; CYCLOSPORIN; FENOFIBRATE; FENOFIBRATE PLUS SIMVASTATIN; IBUPROFEN; INSULIN; ITRACONAZOLE; KETOCONAZOLE; MEGESTROL ACETATE; MELOXICAM; NANOCRYSTAL; NANOTAX; NAPROXEN; NPI 32101; ORIDONIN; PACLITAXEL; PALIPERIDONE; RAPAMYCIN; RILPIVIRINE; RUTOSIDE; SALBUTAMOL; SIMVASTATIN; THERALUX; THYMECTACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLIP;

AEROSOL; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CRYSTAL; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG PELLET; DRUG PENETRATION; DRUG SOLUBILITY; DRY POWDER; EMULSION; ESOPHAGUS CARCINOMA; EYE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIVER CANCER; MAXIMUM PLASMA CONCENTRATION; MUCOADHESION; NEBULIZATION; NONHODGKIN LYMPHOMA; PARTICLE SIZE; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; POWDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SKIN; SPRAY DRYING; SUSPENSION; TABLET; TABLET MANUFACTURE; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 79959350343     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720111795767988     Document Type: Article

References (47)

1. Katteboinaal, S.; Chandrasekhar, V.S.R.; Balaji, S. Drug Nanocrystals: A novel formulation approach for poorly soluble drugs. Int. J. Pharm. Tech. Res., 2009, 1, 682-694.
2. Gao, L.; Zhang, D.; Chen, M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res., 2008, 10, 845-862.
3. Keck, C.M.; Muller, R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm., 2006, 62, 3-16.
4. Liu, F.; Park, J.Y.; Zhang, Y.; Conwell, C.; Liu, Y.; Bathula, S.R.; Huang, L. Targeted cancer therapy with novel high drug-loading nanocrystals. J. Pharm. Sci., 2010, 99(8), 3542-3551.
5. Elan drug technologies. Technology focus. http://www.elandrug-technologies.com/ (Accessed December 7, 2009).
6. Mauludin, R.; Muller, R.H.; Keck, C.M. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J. Pharm. Sci., 2009, 36, 502-510
7. Arunkumar, N.; Decccaraman, M. Nanosuspension technology and its applications in drug delivery; Asian j. Pharm., 2009, 3, 168-173.
8. Rasenack, N.; Muller, B.W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res., 2002, 19, 1894-1900.
9. Bushrab, F.N.; Muller, R.H. Nanocrystals of Poorly Soluble Drugs for Oral Administration. New Drugs, 2003, 5, 20-22.
10. Akkar, A.; Muller, R.H. Formulation of intravenous carbamazepine emulsionsby solemuls technology. Eur. J. Pharm. Biopharm., 2003, 55, 305-312.
11. Fink, J.B. Metered-dose inhalers, dry powder inhalers, and transi tions. Respir. Care, 2000, 45, 623-635.
12. Malcolmson, R.J.; Embleton, J.K. Dry powder formulations for pulmonary delivery. PSTT, 1998, 1, 394-398.
13. Vergote, G.J.; Vervaet, C.; Driessche, I.V.; Hoste, S.; Smedt, S.D.; Demeester, J.; Jain, R.A.; Ruddy, S.; Remon, J.P. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen. Int. J. Pharm., 2001, 219, 81-87.
14. Patravale, V.B.; Date, A.A. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol., 2004, 56, 827-840.
15. Crosera, M.; Bovenzi, M.; Maina, G.; Adami, G.; Zanette, C.; Florio, C.; Larese, F.F. Nanoparticle dermal absorption and toxicity. Int. Arch. Occup. Environ. Health, 2009, 82, 1043-1055.
16. Nanotechnology in cosmetics. http://www.observatorynano.eu/project/filesystem/files/Cosmetics%20report-April%2009.pdf (Accessed December 29, 2009).
17. Araujo, J.; Gonzalez, E.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine, 2009, 5, 394-401.
18. Nagarwal, R.C.; Kant S.; Singh, P.N.; Maiti, P.; Pandit, J.K. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J. Control. Release, 2009, 136, 2-13.
19. First U.S. approval for Elan's NanoCrystal formulation. Pharmaceutical online. http://www.pharmaceuticalonline.com/arti-cle.mvc/First-US-approval-for-Elans-NanoCrystal-formu-0001?VNETCOOKIE=NO (Accessed November 20, 2010).
20. The project of emerging nanotechnology. http://www.nanotech-project.org/inventories/medicine/apps/cancer/emend/ (Accessed November 28, 2010).
21. FDA grants approval for new formulation of Tricor. Science letter. http://www.highbeam.com/doc/1G1-125734903.html (Accessed October 26, 2010).
22. Par pharmaceutical announces FDA approval of Megace ES for anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of AIDS. Par pharmaceuticals. http://investors.parpharm.com/phoenix.zhtml?c=81806&p=irol-newsArticle&ID=1364696&highlight (Accessed July 6, 2010).
23. NUCRYST pharmaceuticals receives FDA clearance of antimicrobial barrier topical cream. Medical news today. http://www.medicalnewstoday.com/articles/77478.php (Accessed November 24, 2010).
24. NUCRYST pharmaceuticals corp. http://www.westaim.com/Theme/Westaim/Files/NUCRYST%20fact%20sheet_Dec%2005% 20FINAL.pdf (Accessed November 26, 2010).
25. ™ for the acute and maintenance treatment of schizophrenia. PR newswire. http://www.high-beam.com/doc/1G1-204815993.html (Accessed Aug 4, 2009).
26. Nanotax clinical trial. Kansas cancer treatment. http://www.kansascancertreatment.org/ (Accessed May 8, 2010).
27. Zolip 0502: Comparison of the combination of fenofibrate and 40 mg simvastatin versus 40 mg simvastatin monotherapy; Solvay Pharmaceuticals. http://www.druglib.com/trial/83/NCT00352183.html (Accessed May 15, 2010).
28. Tibotec Pharmaceuticals Submits New Drug Application for Inves-tigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration. http://www.jnj.com/connect/news/product/Tibotec-Pharmaceuticals-Submits-New-Drug-Application-for-Investigational-Once-Daily-HIV-Treatment-TMC278-to-US-Food-and-Drug-Administration (Accessed December 10, 210).
29. Life sciences news brief. http://www.biopharm.org.tw/ic/can-ada/strategis/05052004/eindex.html (Accessed May 15, 2010).
30. Nanotechnology may deliver once-daily dosage of clozapine. Drug discovery & development. http://www.dddmag.com/news-once-daily-dosing-Clozapine.aspx (Accessed November 30, 2010).
31. Muniyappan, T.; Karatgi, P.; Prabhu, R.; Pillai, R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev. Ind. Pharm., 2008, 34, 1209-1218.
32. Rabinow, B. Nanoedge drug delivery solves the problems of insoluble injectable drugs. Supplement to Scrip World Pharmaceutical News. 2004, 13-16.
33. Mauludin, R.; Muller, R.H.; Keck, C.M. Development of an oral rutin nanocrystal formulation. Int. J. Pharm., 2009, 370, 202-209.
34. Zhang, D.; Tan, T.; Gao, L.; Zhao, W.; Wang, P. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm., 2007, 33, 569-575.
35. Scholer, N.; Krause, K.; kayser, O.; Muller, R.H.; Borner, K.; Hahn, H.; Liesenfeld, O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother., 2001, 45, 1771-1779.
36. Mauludin, R.; Moschwitzer, J.; Muller, R. Development of effervescent and pellet formulations containing ibuprofen drug nanoc-rystals produced by high pressure homogenization. www.aapsj.org/abstracts/AM_2005/AAPS2005-001763.pdf (Accessed September 14, 2009).
37. Liversidge, G.G.; Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm., 1995, 125, 309-313.
38. ® technology. Elan drug delivery. www.aapsj.org/abstracts/Am_2003/AAPS2003-002130.PDF (Accessed September 25, 2009).
39. Bhavna Ahmad, F.J.; Khar, R.K.; Sultana, S.; Bhatnagar, A. Techniques to develop and characterize nanosized formulation for salbu-tamol sulfate; J. Mater. Sci. Mater. Med., 2008, 20, 71-76.
40. Kevin, D.; Ostrander, H.; Bosch, W.; Bondanza, D.M. An in-vitro assessment of a nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm., 1999, 48, 207-215.
41. Gao, L.; Zhang, D.; Chen, M.; Zheng, T.; Wang, S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev. Ind. Pharm., 2007, 33, 1332-1339.
42. Liu, Y.; Huang, L.; Liu, F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol. Pharm., 2010, 7(3), 863-869.
43. Liversidge, E.M.; McGurk, S.L.; Liversidge, G.G. Insulin nanopar-ticles: a novel formulation approach for poorly water soluble zn-insulin. Pharm. Res., 2004, 21, 1545-1553.
44. Preparation of nanocrystals of glyburide by high energy controlled salting out (HECSO) process and their characterization. www.aapsj.org/abstracts/AM_2007/AAPS2007-001029.PDF (Accessed September 24, 2009).
45. Xiong, R.; Lu, W.; Li, J.; Wang, P.; Xu, R.; Chen, T. Preparation and characterization of intravenously injectable nimodipine nano-suspension. Int. J. Pharm., 2008, 350, 338-343.
46. Hecq, J.; Deleers, M.; Fanara, D.; Vranckx, D.; Amighi, K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm., 2009, 299, 167-177.
47. Langguth, P.; Hanafy, A.; Frenzel, D.; Grenier, P.; Nhamias, A.; Ohlig, T.; Vergnault, G.; Spahn-Langguth, H. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm., 2005, 31, 319-329.